h/t: Discoblog
Tuesday, March 29, 2011
Wednesday, March 23, 2011
Canadian Wait Times
80% doesn't seem so terrible, unless of course you're in the 20% where wait times can be as much as three times the recommended benchmark. And if you're suffering with a hip fracture, 48 hours might seem like an eternity even if it is the evidence-based benchmark. Generally, although there is variation, Ontario, Quebec and British Columbia are your best bets for receiving timely care. Click the picture to enlarge or check out the full report for a more detailed look.
The study also looked at CT and MRI imaging, though there are currently no pan-Canadian benchmarks. In Ontario, where the provincial target for non-emergency, non-urgent CT scans is 4 weeks, the median wait time is under 10 days and the 90th percentile is about 35 days and trending downwards. MRIs on the other hand, with the same non-emergency, non-urgent target of four weeks have a median wait time of close to 40 days with the 90th percentile mark at 120. And these times have gotten longer over recent years.
Other items of note: If you need a knee replacement, avoid Nova Scotia (only 42% meet benchmark wait times). Ditto for cataract surgery in Alberta (48%). And PEI doesn't offer cardiac services? No wonder Matthew Cuthbert didn't make it.
Posted by
Kamel
at
5:21 PM
2
comments
Labels: canada, universal healthcare
Thursday, March 17, 2011
Funny gene name browser
chadonnay. chablis, frascati, merlot, retsina, riesling, cabernet, grenache, chardonnay, chianti, pinotage, sauternes, weissherbst, zinfandel, freixenet and yquem: mutations in these loci cause defects in hematopoiesis (production of blood cells).
cheap date. Mutants are especially sensitive to alcohol (which, seriously speaking, might be a feature to avoid in a date). Interestingly, another name for the gene is amnesiac, as mutants also have a poor memory.
half pint. Cheryl Van Buskirk writes: "The mutant ovaries produce egg chambers that contain eight instead of sixteen cells. Since there are 16oz in a pint, we figured it was a pretty fitting name. Half pint is also an informal term for a very short person, and it so happens that the mutant eggs were indeed quite short. Sadly, the official gene name has since become Dmel/pUf68, based on its molecular weight and homology to poly-U binding splicing factors, and the name half pint is considered a synonym."
Posted by
Anonymous Coward
at
2:59 PM
0
comments
Labels: funny, gene names, st-patrick
Friday, March 11, 2011
Drug Reps: The Telemarketer Script
The full text is freely available at the above link.
Posted by
Kamel
at
5:22 PM
1 comments
Labels: pharma
A Study on Beer Taste? Sign Me Up!
This study aimed to test the much-pronounced but poorly supported theory that “Guinness does not travel well.” A total of 4 researchers from 4 different countries of origin traveled around the world for 12 mo to collect data on the enjoyment of Guinness and related factors. The main outcome was measured on a Visual Analogue Scale (VAS) from 0 (enjoyed it not at all) to 100 (enjoyed it very much). A total of 103 tastings were recorded (42 in Ireland, 61 elsewhere) in 71 different pubs spread over 33 cities and 14 countries. The enjoyment of Guinness consumed in Ireland was rated higher (74 mm VAS) than outside Ireland (57 mm; P < 0.001). This difference remained statistically significant after adjusting for researcher, pub ambience, Guinness appearance, and the sensory measures mouthfeel, flavor, and aftertaste. This study is the first to provide scientific evidence that Guinness does not travel well and that the enjoyment of Guinness (for our group of nonexpert tasters) was higher when in Ireland. Results, however, are subject to further verification because of limitations in the study design.This is a pretty fun bit of research though, as the authors point out, very limited. For example, there is no reporting on a "control" beer to see if their findings are Guinness specific. Strangely, the authors attempted to adjust for pub ambience (which was ranked higher in pubs in Ireland) but seemed to ignore the fact that while in Ireland they consumed more alcohol before testing than in other countries (2.5 versus 1.4, P = 0.035), a factor that can undoubtedly affect perception and overall enjoyment. The authors point out the fact that Guinness is brewed in nearly 50 countries around the world, so the question "Does Guinness travel well?" may not be appropriate. And of course expectations and blinding issues run rampant in a study like this. Clearly the authors should recruit my beer-drinking expertise the next time they embark on this type of research.
Other items of note: The price of a pint of Guinness was not significantly different in Ireland compared to the other countries visited (£3.66 versus £3.83) and none of the pints served in Ireland had the head stamped with a shamrock or other design, compared to 13.1% of non-Irish pours (P = 0.015)
I have to say that while journals often do publish short "fun" pieces, I was a bit surprised to see this study appear in a peer-reviewed journal instead of a blog post. I just hope the editors are as kind when I submit my upcoming study of the best local beers here in Ottawa.
Posted by
Kamel
at
12:56 PM
0
comments
Labels: beer
Tuesday, March 08, 2011
Undergrads Will Believe Anything. If it's Well Written
Chesney and Su gave 269 undergraduate students – 182 in the UK, 87 in Malaysia - a fake story chronicling a blogger's discovery of, and subsequent battle with, nail fungus (ew?). The posts were identical except for the blogger's biographical information running along the top. Here, the researchers had three types of bio: 1) a pseudonym only 2) a pseudonym, age, and sex, or 3) the blogger's “real” name, age, sex, email address and photograph.Each blogger was graded by the students on criteria such as trustworthiness and credibility. The authors of the study found that fully-identifiable bloggers were rated no better than their pseudonymous counterparts. Of course, as the SciAm piece points out, it could just be that bloggers in general have such low credibility that adding a real name and a photo just doesn't help. And while the results seem to support the idea that pseudonymous bloggers have just as much (perceived) credibility as RealName bloggers, it says nothing of other potential anti-pseud arguments - like the ease with which one can be an unbridled asshole when there is no fear of repercussion. We're fine with that though, since what's the point of being a pseudonymous asshole when nobody believes you?
The study also looked at the effect of presentation on perceived credibility.
This time respondents were shown one of two blog posts which conveyed exactly the same information and revealed exactly the same information about the blogger. One post introduced a number of spelling/grammar/punctuation errors.In this case, the well-written posts were graded higher than those riddled with spelling and grammatical errors. So if you're going to be posting BS online, make sure it's well-written if you want people to believe it. (That's been my secret all along)
Of course, the real moral of the story is that undergrads will believe anything, as long as you run it through spell check.
One thing to note, though, is that the study seemed to use personal blog-type entries, like those you might find in an online diary. Science or medical blog posts, where credentials could add certain weight to delivered information, may be graded differently when it comes to pseudonymous credibility. That would be an interesting study to see, but one that wouldn't affect the Bayblab since our posts are so well-written they've got to be true.
Posted by
Kamel
at
10:48 AM
0
comments
Thursday, March 03, 2011
Cancer Carnival #43
Kicking things off is Biotunes who writes about the PSA screening test for prostate cancer and how it falls short.
Our overzealous “war” on prostate cancer in particular has been devastating to the quality of life of millions of men: it has been estimated that 48 men are treated to save one life from prostate cancer.Issues with screening techniques (such as false positive rates) have been discussed before on this blog and last month's Cancer Research Blog Carnival contained a post about genetic determinants of baseline PSA levels - a subject that really underscores one of the issues raised in the Biotunes post.
Dwarfism seems to be a big topic this month with two posts discussing dwarfism in Ecuador and a link between diabetes and cancer.
Can a gene that causes dwarfism also confer major health benefits? Perhaps, according to a new study showing that a group of extremely short people in Ecuador get no diabetes, even though they are unusually obese.This study was also sent to us in a different post at Genome Engineering.
The 22-year study of people living in villages on the slopes of the Andes mountains also found just one case of cancer in the 99 patients it tracked, many fewer than among non-dwarf relatives.
The absence of two of the worst diseases of aging was strong evidence that the mutation that causes what’s called “Laron syndrome” has an upside.
Genome Engineering also sends us a news brief about a study looking at the genetics of inflammatory bowel disease, which can increase the risk of bowel cancer.
Our friends at Highlight HEALTH have a post up about the drug Crizotinib and a movement towards personalized cancer care.
Unfortunately, though perhaps not surprisingly, drugs like crizotinib and Gleevec cannot be the last line of defense. Once they are administered, the kinases they target can mutate to resistant them. The third research study published in the NEJM, by Choi et al., enumerates the mutations in EML4-ALK that confer such resistance to crizotinib [5]. Additional kinase inhibitors are being developed to act as backup therapies for both crizotinib and Gleevec once drug resistance has occurred.The post points out the importance of tumor gene expression profiling to determine which drugs are best suited for individual treatment.
Finally, a guest post at Hematopoiesis discusses the role of cancer stem cells in mesothelioma, a cancer typically traced back to asbestos exposure.
Recent research has explored the idea that cancer stem cells (CSC) play a role in the metastasis of mesothelioma tumors. Researchers at the University of Tokyo’s Division of Clinical Immunology transferred malignant mesothelioma cells into mice and studied the cell lines as they developed. They found that many of the cells displayed markers for CSC such as SP, CD9, CD24, and CD26. The cells with those markers were also found to generate larger tumors.That's it for this month's Cancer Research Blog Carnival. For older editions, visit the Carnival Homepage. Don't forget, the CRBC has subscription options; you can follow by email or RSS feed. An aggregated feed of credible, rotating health and medicine blog carnivals is also available. For a broader collection of science-related blog carnivals, sign up for the Science, Medicine, Environment and Nature Blog Carnival Twitter Feed.
Posted by
Kamel
at
4:53 PM
2
comments
Labels: blog carnival, cancer research
Friday, February 25, 2011
Friday, February 04, 2011
Cancer Carnival #42
First off, is a pair of posts from the 23andMe blog, The Spittoon. The first reports on genetic variations associated with different prostate-specific antigen levels in men.
To further complicate matters, the major screening test for prostate cancer, the prostate-specific antigen (PSA) test, is imperfect. This test detects the levels of PSA, a protein produced by prostate cells, in the blood. Cancerous prostate cells generally produce more PSA than normal prostate cells, leading to higher blood levels of PSA. However, prostate cancer is not the only condition that can cause PSA levels to rise.The post then describes a recent study describing genetic variants that can lead to different baseline PSA levels. The second post examines genetic variants associated with skin cancer.
A recent study in the journal Pigment Cell and Melanoma Research looked at variants linked to pigmentation (hair color, eye color, skin color), skin sensitivity to sun, and freckling and moles as they related to different types of skin cancer. They found that melanoma is associated with two different kinds of variants: those related to skin pigmentation and sensitivity to sun, and those related to the number and type of moles an individual has.Next up, HighlightHEALTH describes peer-reviewed research suggesting that daily aspirin may reduce the risk of certain cancers.
It is old news that aspirin is good for your heart. But a recent report published in The Lancet, the premiere medical journal in the United Kingdom, claims that at least 75mg of aspirin every day can also reduce the risk of developing many different types of cancers.The described study is a meta-analysis of 8 clinical trials, including over 25,000 patients.
Finally, Respectful Insolence has a post up discussing an FDA report on a link between breast implants and cancer. Orac takes a look at the actual evidence
In fact, the most significant risk due to breast implants is not the risk of systemic diseases, such as autoimmune diseases or cancer. Far more significant is the rate of local complications, such as capsular contracture or implant rupture. Due to such complications, many women with implants require reoperation. Indeed, reoperation rates have been estimated to be as low as 3% after seven years to as high as 20% over three years. These are by far the most significant risks due to breast implants.Read the hole post for an analysis of the FDA report and the existing evidence of a cancer connection.
That's it for this month's Cancer Research Blog Carnival. For older editions, visit the Carnival Homepage. Don't forget, the CRBC has subscription options; you can follow by email or RSS feed. An aggregated feed of credible, rotating health and medicine blog carnivals is also available. For a broader collection of science-related blog carnivals, sign up for the Science, Medicine, Environment and Nature Blog Carnival Twitter Feed.
Posted by
Kamel
at
4:17 PM
5
comments
Labels: blog carnival, cancer research
Tuesday, January 25, 2011
Tin pest
Posted by
Rob
at
11:05 PM
2
comments
Monday, January 24, 2011
Sunday, January 23, 2011
Friday, January 07, 2011
Cancer Carnival #41
First up, the Genome Engineering blog has a post up on turning skin cells into blood progenitors as a possible source of replacement cells in patients with cancers of the blood.
Because they can become any blood cell type, haematopoietic progenitor cells from bone marrow are used to repopulate the blood in patients that have leukaemias or lymphomas, other blood cancers and inborn defects of the blood or immune system. Researchers at McMaster University, Canada, have developed a technique to turn skin cells into blood progenitor cells.This is a topic I previously covered at the Stem Cell Network blog, which also raises a question of how this will affect a need for blood donors.
Sticking with stem cells, the Hematopoiesis blog asks, "Can we uncouple stemness and carcinogenesis?"
The last two decades of research have unveiled remarkable similarities between malignant cells and stem cells. It becomes more evident with development of the cancer stem cell concept. Last year I’ve asked a question about possible separation of normal stem cells from cancer cells based on cell surface markers. Despite the identification of new targets, this approach is still elusive. Now, I’d like to talk about molecular regulation and signaling in normal stem cells and cancer cells.The post details the similarities between malignant cells and stem cells and discusses a recent paper highlighting their differences in gene regulation.
At HighlightHEALTH, Walter has a post up about the potential revokation of marketing clearance for the cancer drug Avastin.
On one side, you have critics of the FDA accusing them of rationing healthcare while on the other side, you have comparative effectiveness research showing that there’s no statistically meaningful difference in the survival of patients receiving Avastin plus chemotherapy compared to chemotherapy alone.The post examines some of the data used to support Avastin use, as well as the economic impact of such an expensive treatment.
That's it for this month's Cancer Research Blog Carnival. For older editions, visit the Carnival Homepage. Don't forget, the CRBC has subscription options; you can follow by email or RSS feed. An aggregated feed of credible, rotating health and medicine blog carnivals is also available. For a broader collection of science-related blog carnivals, sign up for the Science, Medicine, Environment and Nature Blog Carnival Twitter Feed.
Posted by
Kamel
at
2:38 PM
0
comments
Labels: blog carnival, cancer research
Thursday, December 30, 2010
Eel-powered Christmas Lights
Posted by
Kamel
at
9:07 AM
12
comments
Labels: video
Sunday, December 19, 2010
Economist view of academics
Posted by
Rob
at
12:18 PM
26
comments
Thursday, December 09, 2010
"In the real world, that would be considered a mental disorder!"
Posted by
Kamel
at
2:20 PM
18
comments
Labels: graduate school, humor
Tuesday, December 07, 2010
Monday, December 06, 2010
Arsenic-based life? Not so fast.
Posted by
Kamel
at
5:07 PM
10
comments
Labels: alternative biochemistry
Friday, December 03, 2010
Cancer Carnival #40
The holidays are upon us, and it's a short carnival this month, so we'll kick things off with a short post. Alexey Bersenev at Stem Cell Assays points us to a new review of aldehyde dehydrogenase in stem cells.
Aldehyde dehydrogenase (ALDH) is a potent and “popular” marker for both normal adult and cancer stem cells in rodents (mice) and human. I was happy to find very recent and comprehensive review about role of ALDH in human stem cells.ALDH1, it seems, is not just a convenient marker of normal and cancer stem cells, but may play an important role in stem cell physiology.
Speaking of stem cells, I have a post up at the Stem Cell Network blog describing a new method for interconversion between cell types without first producing an induced pluripotent stem (iPS).
Because these cells never enter a pluripotent state, they were shown to not give rise to teratomas, and the resulting engraftments lacked leukemia stem cell properties, this suggests a decreased cancer risk compared to other alternatives that retain tumour potential.At Respectful Insolence, Orac describes the tolls of second-hand smoke.
One aspect of the results of this study that were particularly disturbing is that deaths due to secondhand smoke were skewed toward poor and middle-income countries, where children tended to die of lower respiratory infections associated with secondhand smoke. In Europe's high-income countries, only 71 child deaths were recorded for this study, while 35,388 deaths were in adults. In contrast, in Africa, there were an estimated 43,375 deaths potentially attributable to secondhand smoking in children compared with 9,514 in adults.Orac also discusses flaws in the described study, but overall evidence points to the dangers of second-hand smoke inhalation. Meanwhile at HighlightHEALTH, with over 1 billion smokers in the world producing second-hand smoke, Walter Jessen points out that tobacco prevention funding is at a 10-year low.
According to the latest data from the Federal Trade Commission, tobacco companies spend $12.8 billion a year on marketing; that equates to $25 tobacco companies spend to market tobacco products for every $1 the states spend to fight tobacco use. Perhaps not surprisingly, a recent CDC study reports that the number of adult smokers dropped between 2000 and 2005, but the adult smoking rate has stalled at 20-21% since 2005.Given that tobacco is the number one cause of preventable death in the US, and the toll of second-hand smoke on non-users described above, this isn't great news.
Finally, ERV talks about a paper discussing Merkel Cell Polyomavirus and it's role in Merkel cell carcinoma.
This paper isnt perfect. I have a lot of issues with it too-- BUT! I think it is a fantastic step in the right direction of establishing the role of a virus in a cancer and establishing the biochemistry of that interaction. This not only helps with the logic (there are some logical issues I have with XMRV-->prostate cancer) so people believe you, but if you elucidate the biochemistry/genetics/physiology, taking the issue beyond "WE CAN FIND THE VIRUS IN 80% CANKERS!", you can figure out potential avenues of treatment.Read the post for the full story.
That's it for this month's Cancer Research Blog Carnival. For older editions, visit the Carnival Homepage. Don't forget, the CRBC has subscription options; you can follow by email or RSS feed. An aggregated feed of credible, rotating health and medicine blog carnivals is also available. For a broader collection of science-related blog carnivals, sign up for the Science, Medicine, Environment and Nature Blog Carnival Twitter Feed.
Posted by
Kamel
at
1:48 PM
2
comments
Labels: blog carnival, cancer research
Wednesday, December 01, 2010
Gay Prostates
As an aside, can we get any pics of great (creepy) Movember mustaches now that its all over?
Posted by
Rob
at
10:38 PM
1 comments

Podcast

0 comments:
Post a Comment